saving life through targeted therapies
Sauvie is a mission-driven biotechnology company with a focus to discover, develop and deliver innovative, highly targeted single-domain antibody based therapies that harness proven disease pathways.
Latest News
A high affinity and specificity anti-her2 single-domain antibody (VHH) that targets trastuzumab’s epitope
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications – PubMed (nih.gov)https://pubmed.ncbi.nlm.nih.gov/37632647/
Research into novel BiKE:HER2/CD16a nanobody published in Frontiers in Immunology
Research into novel BiKE:HER2/CD16a nanobody published in Frontiers in Immunology Arash Hatefi, PharmD, PhD, Professor, Department of Pharmaceutics at Rutgers’ Ernest Mario School of Pharmacy
Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager
SHORT HILLS, N.J., Oct. 24, 2022/PRNewswire/ – Sauvie Inc. (the “Company”), a mission-driven biopharmaceutical company focused on sustainably building an immuno-oncology company, today announced Sauvie’s subsidiary, Sauvie BiKE LLC, has entered into an exclusive license agreement with Rutgers, The State University of New Jersey (“Rutgers”) for the development and worldwide commercialization rights of a bi-specific natural killer (NK) cell engager technology in the field of oncology.
